Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: consult-transplant versus consult- no-transplant analysis. Issue 3 (March 2015)

• Record Type: Journal Article
• Authors: Poon, Michelle L.; Fox, Patricia S.; Samuels, Barry I.; O'Brien, Susan; Jabbour, Elias; Hsu, Yvonne; Gulbis, Alison; Korbling, Martin; Champlin, Richard; Abruzzo, Lynne V.; Bassett, Roland L.; Khouri, Issa F.
• Is Part Of: Leukemia & lymphoma. Volume 56:Issue 3(2015:Mar.)
• Page Start: 711
• Page End: 715
• Publication Date: 2015-03
• Subjects: CLL -- 17p− -- allogeneic transplant; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.3109/10428194.2014.930848
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Allogeneic stem cell transplant (alloSCT) can overcome the adverse prognosis of chronic lymphocytic leukemia with 17p deletion (17p− CLL). However, its applicability remains unclear. Since 2007, our leukemia service has referred patients with 17p− CLL for alloSCT at presentation. In this study, the outcomes of these patients were reviewed retrospectively to determine whether they underwent alloSCT and why patients did not undergo alloSCT. Fifty-two patients with 17p− CLL who were referred to the transplant service from 2007 to 2010 were identified. Of these patients, 32 (62%) did not undergo alloSCT, mainly because of treatment- or disease-related complications ( n = 15). The 2-year post-referral overall survival rates of the alloSCT and non-SCT groups were 64% and 25%, respectively ( p = 0.001). These findings suggest that while alloSCT is an effective therapy in patients with 17p− CLL, pre-SCT complications may preclude a significant proportion of patients from undergoing the procedure.